Abstract
Of the adeno-associated viruses (AAVs), AAV9 is known for its capability to cross the blood–brain barrier (BBB) and can, therefore, be used as a noninvasive method to target the central nervous system. Furthermore, the addition of the peptide PhP.B to AAV9 increases its transduction across the BBB by 40-fold. Another neurotropic serotype, AAV5, has been shown as a gene therapeutic delivery vehicle to ameliorate several neurodegenerative diseases in preclinical models, but its administration requires invasive surgery. In this study, AAV9-PhP.B and AAV5-PhP.B were designed and produced in an insect cell–based system. To AAV9, the PhP.B peptide TLAVPFK was added, whereas in AAV5-PhP.B (AQTLAVPFKAQAQ), with AQ-AQAQ sequences used to swap with the corresponding sequence of AAV5. The addition of PhP.B to AAV5 did not affect its capacity to cross the mouse BBB, while increased transduction of liver tissue was observed. Then, intravenous (IV) and intrastriatal (IStr) delivery of AAV9-PhP.B and AAV5 were compared. For AAV9-PhP.B, similar transduction and expression levels were achieved in the striatum and cortex, irrespective of the delivery method used. IStr administration of AAV5 resulted in significantly higher amounts of vector DNA and therapeutic miRNA in the target regions such as striatum and cortex when compared with an IV administration of AAV9-PhP.B. These results illustrate the challenge in developing a vector that can be delivered noninvasively while achieving a transduction level similar to that of direct administration of AAV5. Thus, for therapeutic miRNA delivery with high local expression requirements, intraparenchymal delivery of AAV5 is preferred, whereas a humanized AAV9-PhP.B may be useful when widespread brain (and peripheral) transduction is needed.
Comparison of AAV5 vs. AAV9-PhP.B delivered intravenous or intrastriatal. Irrespective of the two delivery methods, similar transduction in the cortex and striatum is achieved with AAV9-PhP.B. In contrast, AAV5—when injected directly into the striatum—obtains high transduction levels in the cortex and striatum.
Introduction
Neurodegenerative diseases are a heterogeneous group of multisystem disorders affecting the central nervous system (CNS), and treatment options for those are limited. An important and challenging aspect of the treatment of these diseases is efficient drug target delivery. Viral vectors harboring therapeutic nucleic acid molecules have to be delivered to the CNS to accomplish their therapeutic action at the desired site. The delivery of viral vectors is a part of molecular neurosurgery, thereby treating disease on a molecular level. Various disease-modifying therapies are in the (pre)clinical stage for neurodegenerative diseases based on adeno-associated virus (AAV) as the delivery tool of nucleic acids (; ).
One of the examples of such a preclinical program is for the treatment of Huntington’s disease (HD). Intrastriatal (IStr) delivery of AAV carrying a huntingtin silencing miRNA resulted in a successful reduction in huntingtin mRNA and protein in the brains of mouse and minipig HD models (; ). The produced miRNA lowered cytoplasmic and nuclear gene expression and showed therapeutic spread through extracellular vesicles without off-target effects (). This miRNA technology has also been used as silencing strategies for Spinocerebellar Ataxia Type 3 () and Amyotrophic Lateral Sclerosis (ALS) ().
The direct IStr administration of AAV has been used to supply the brain locally with the therapeutic doses of the miRNA (; ). However, this invasive intervention requires a well-equipped and trained neurosurgical team. Intravenous (IV) administration would be an attractive alternative since it is less invasive. Nevertheless, an AAV capsid that can cross the blood–brain barrier (BBB) is required when targeting the CNS by IV administration. AAV9 has been shown to have this capability, especially in neonates (). The number of vector copies needed to reach therapeutic doses in the brain may lead to elevated aminotransferase levels, an indicator of liver damage (). For the probable cause of systemic adverse events, it is currently challenging to use IV administration of AAV9 for neurodegenerative diseases in adults.
Various attempts have been undertaken to improve the capability and efficiency of AAV to cross the BBB. A variant of AAV9, named AAV9-PhP.B, was reported to enhance brain tissue transduction, such as the cortex, by 40-fold compared with its AAV9 ancestor (). The enhancement of AAV9 by PhP.B appears to occur only in rodents (), with a preference for the C57Bl/6 strain, the strain in which PhP.B was developed and tested (). Studies in nonhuman primates () and marmosets () have not shown any increase in the transduction levels of AAV9-PhP.B when compared to AAV9. PhP.B binds to the Ly6a receptor, a GPI (glycophosphatidylinositol)-anchored surface protein highly expressed in the microvascular endothelial cells of C57Bl/6 mice (; ). Unfortunately, Ly6a is absent in endothelial cells of primates (), which explains why no increase is observed in BBB crossing compared with AAV9. These results limit the use of PhP.B-containing vectors in humans. However, AAV9-PhP.B can still be used as a benchmark for preclinical studies in C57Bl/6 mice. The knowledge gained from these studies could be used to rationally develop novel vectors that cross the BBB.
PhP.B is constructed by inserting a 7-mer peptide at position I-588. The insertion site is located outside of the capsid on the tip of a loop at the 3-fold axis of symmetry, facilitating interaction with the receptors of targeted cells. AAV9-PhP.B has shown to be functional in mouse models. For example, AAV9-PhP.B-based gene therapy has been shown to reduce α-synuclein pathology in a preclinical mouse model ().
We hypothesized that the addition of PhP.B could also be used to enhance BBB crossing of other serotypes. showed that the natural serotypes of AAV2 and AAV5 do not cross the BBB even in neonatal mice (). AAV5 is the most divergent of the naturally occurring AAVs. After local administration, AAV5 shows widespread transduction of the brain (), making this vector a useful candidate to test the limits of PhP.B. This widespread targeting has been shown in a variety of animal models such as mice, rats, nonhuman primates, and minipigs (; ; ; ). Furthermore, AAV5 has been shown to specifically target astrocytes and specialized neurons such as dopaminergic and motor neurons derived from the human-induced pluripotential stem cells (). In in addition to neuronal tropism AAV5 could be delivered systemically in a noninvasive manner would be ideal. Therefore, PhP.B was added to AAV5 to explore the enhanced crossing of the BBB.
First, AAV5 and AAV9 were modified by inserting the 7-mer PhP.B, and the vectors were produced in the baculovirus expression system. This system facilitates scaling up production (). Then, these new capsids were evaluated in vitro with respect to the green fluorescent protein (GFP) expression and dose–response quantified by luciferase activity. The capability of capsids to cross the BBB of mice was assessed at a relatively low dose to remain below the saturation threshold. Finally, IStr and IV delivery of AAV5 and AAV9-PhP.B were compared for transduction and transgene expression in the cortex and striatum.
Materials and Methods
Vector Design and Production
The AAV9-PhP.B transfer plasmid was designed by adding the PhP.B peptide to VP1 between amino acids 588 and 589 of AAV9 adapted for baculovirus production. AAV5-PhP.B was constructed by swapping in the 13-mer loop containing PhP.B, as described in the study of , and publicly available as sequence KU056473, shown in Figure 1A. Baculovirus was produced by homologous recombination with the transfer plasmids, as described earlier (; ). Expression cassettes containing either GFP, Luc, or miRNA were generated correspondingly. To generate AAV, Spodoptera frugiperda (SF) SF+ cells were triple-infected with baculovirus containing capsid, expression cassette, and the replicon enzyme. At 72 h postinfection, cells were lysed, and the clarified lysate was purified on the ÄKTA explorer (FPLC chromatography system, GE healthcare, United Kingdom) using AVB sepharose (GE healthcare, United Kingdom). The vectors were titrated by SYBR Green for quantitative PCR (qPCR) using a primer pair binding to the promoter region CAG (forward primer: GAG CCG CAG CCA TTG C and reverse primer: CAC AGA TTT GGG ACA AAG GAA GT) or CMV (forward primer: AATGGGCGGTAGGCGTGTA and reverse primer: AGGCGATCTGACGGTTCACTAA) and expressed as genome copies per ml (GC/ml).
FIGURE 1
In vitro Analysis
Of note, 1 × 105 CHO Lec-2 cells were seeded in a 24-well plate and inoculated and incubated overnight. On the following day, cells were inoculated with 1 × 1011 GC/well for a multiplicity of infection (MOI) of 1 × 106 in triplicate for each capsid. GFP expression was visualized 3–7 days postinoculation. CHO Lec-2 cells were seeded at a density of 2.5 × 104 cells/well in duplicate in a black 96-well plate and inoculated in a 10-fold serial dilution starting at MOI of 4 × 106 of each capsid containing a luciferase expression cassette. Plates were incubated at 37°C for approximately 20 h and subsequently analyzed. 1 × 105 HuH-7 cells or 5 × 104 CHO Lec-2 cells were seeded in triplicate in two 24-well plate and inoculated with an MOI of 1 × 105 incubated for 20 h. One plate was used for luciferase analysis and the other for DNA.
Luciferase assay was carried out using the One-Glo Luciferase Assay System (E6120, Promega, Madison, United States) according to the instruction of the manufacturer. DNA was extracted from cell lysate using the AllPrep kit (QIAGEN, Germany) according to the instruction of the manufacturer. Vector DNA was detected by qPCR using SYBR Green primers binding to the CMV promoter (forward primer: AAT GGG CGG TAG GCG TGTA and reverse primer: CAC AGA TTT GGG ACA AAG GAA GT).
Animal Studies
All animal studies described were approved by the local ethics committee for animal experimentation. Female, young adult C57Bl/6 mice (Janvier Labs, France) were used for all experiments. For IV administration, 8 μl/g body weight of each viral vector preparation was injected into the tail vein. For IStr administration, animals were anesthetized with Hypnorm/Dormicum, and an incision was made in the skin of the head. A small hole was drilled in the skull, and the striatum was stereotactically approached. A 2 μl of vehicle or AAV-miRNA was injected into the striatum in both hemispheres (Anteroposterior = +0.8 mm; mediolateral = ±1.8 mm; Dorsal/Ventral = −3.0 mm) using a 30-Ga needle (BD, Becton, Dickinson and Company, NJ, United States) and attached by tubing to a 10-μl Hamilton syringe at a rate of 0.5 μl/min. After surgery, mice were administered buprenorphine (Temgesic) as pain relief. An overview of injection routes, vectors, and dosage used is given in Table 1.
TABLE 1
| Study | Vectors | Injection route | Volume (μl) | Total dose (GC/mouse) | Titer (GC/ml) |
| Comparison of capsids at a low dose | AAV5-GFP AAV5-PhP.B-GFP AAV9-GFP AAV9-PhP.B-GFP | IV | 200/25 gr | 2,5 × 1011 | 1 × 1012 |
| AAV9-PhP.B transduction of CNS | AAV9-PhP.B-GFP | IV | 200/25 gr | 4 × 1012 | 1,6 × 1013 |
| AAV5 vs. AAV9-PhP.B | AAV5-miRNA | IV | 160/20 gr* | 4 × 1012 | 2,7 × 1013 |
| AAV9-miRNA | IStr | 4 (2/hemisphere) | 1 × 1011 | 2,7 × 1013 |
Overview of injection routes, vectors, and dosage used.
*Mice were 6 weeks old at the start of the experiment.
Vector Distribution and GFP Expression
At 4 or 6 weeks postinjection, animals were humanely euthanized, and organs were dissected and frozen at −80°C. For the first experiment, in comparison with capsids at a low dose, the left hemisphere was used for molecular analysis and the other half fixed in 4% paraformaldehyde for histology. For the last experiment, both left and right hemispheres were frozen for the vector distribution analysis.
Organ pieces were pulverized to a powder using the cryoPREP system (Covaris, Woburn, MA, United States). Approximately ± 10-mg powder was used to extract DNA using the DNeasy® 96 Blood and Tissue kit (QIAGEN, Germany). The presence of vector DNA was detected and quantified by qPCR using TaqMan primers and probe binding to CAG promoter (forward primer: GAG CCG CAG CCA TTG C, reverse primer: CAC AGA TTT GGG ACA AAG GAA GT, and probe: ATG GTA ATC GTG CGA GAG GGC GC). Vector DNA genome copies per μg DNA were quantified by interpolating from a standard line prepared from the plasmid of the expression cassette. RNA was isolated from powder using the RNeasy® Plus Mini Kit (74136) from QIAGEN, Germany. Total RNA was reverse-transcribed to cDNA using the Maxima First-Strand kit (R1362, Thermo Fisher, Waltham, MA, United States), RNA expression was quantified by using primers binding to GFP (forward primer: AGC AAA GAC CCC AAC GAG AA, reverse primer: GCG GCG GTC ACG AAC TC, and probe: CGC GAT CAC ATG GTC CTG CT) and GAPDH (TaqMan expression array from Thermo Fisher, Paisley, United Kingdom) as a housekeeping gene for reference. RNA expression was calculated using the ΔCT method normalized to the housekeeping gene.
microRNA TaqMan Assay
For the detection of the expressed microRNA, pulverized cortical and striatal tissue was subjected to the Direct-zol kit (R2061, ZYMO Research, Irvine United States) according to the protocol of the manufacturer. RNA was reverse-transcribed into cDNA using the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, 4366597, Waltham, MA, United States). Diluted samples of each cDNA sample were subjected to TaqMan qPCR using a primer–probe set specific for miRNA and an internal control miRNA (U6).
Graphs, Statistical Analysis, and Figures
The statistical analysis and graphs were generated using GraphPad, www.graphpad.com [GraphPad Prism version 8.4.2. (679) for Windows, GraphPad Software, San Diego, CA, United States]. To compare groups, a one-way ANOVA was used, followed by the Tukey’s multiple comparisons test. Figures with cartoons were created using biorender.com. Graphical Abstract was made by Sabela DeScience.
Histology
Of note, 24–48 h after immersion fixation in 4% paraformaldehyde, brains were embedded in 10% gelatin (Difco) in a phosphate-buffered saline (PBS). Embedded tissue was sectioned on a Vibratome. Coronal sections were collected in PBS in series at a thickness of 50 μM. Immunohistochemistry (IHC) was performed on the free-floating sections. Endogenous peroxidase block was performed by incubating sections for 1 h in 1% H2O2/30% ethanol in PBS. Sections were washed three times with washing buffer (PBS/0.05% Tween). Nonspecific blocking was performed by incubating sections for 1 h in PBS supplemented with 4% bovine serum albumin (BSA) and 5% normal goat serum (NGS). Subsequently, sections were incubated overnight with primary antibody against GFP (Abcam ab290, Cambridge, United Kingdom), diluted 1:1000 in PBS/1% BSA/1.25% NGS/0.5% Tween, and incubated for 1 h with horseradish peroxidase (HRP)-conjugated anti-rabbit before detection with 3,3′-diaminobenzidine (DAB) according to instructions of the manufacturer (Dako EnVision kit K4009, Agilent, Santa Clara, CA, United States). Subsequently, they were dehydrated through ethanol series, xylene, and embedded in Entellan before microscopic analysis.
Results
Design and in vitro Testing of AAV-PhP.B Capsids
To ensure that the vectors could be adapted to our production system, PhP.B was added to AAVs adapted for the baculovirus expression system. For AAV9, PhP.B was added at the same position, I-588, as described in the study of .
Earlier attempts to modify AAV5 at the corresponding position I575 were not successful (). An alignment of AAV5 and AAV9-PhP.B shows sequence similarity outside of the known variable regions, forming a loop at the 3-fold axis of symmetry (Figure 1A). This loop facilitates interaction with the receptors of targeted cells. To add this loop to AAV5, AAV5-PhP.B (i.e., AQTLAVPFKAQAQ) was made by swapping in the flaking regions of AAV9-PhP.B containing the peptide (Figure 1A).
The new capsids were tested for transduction efficacy in vitro using Chinese hamster ovary (CHO) Lec-2 cells and HuH-7 cells. Having an easily accessible nonmurine cell line is essential to set up future potency experiments. CHO Lec-2 cells are deficient in monophosphate-SA (CMP-SA) Golgi transporter. Therefore, N- and O-glycans of these cells only contain galactose residues, as depicted in Figure 1B. CHO Lec-2 cells are suitable for studying AAV9 transduction in vitro as this virus uses galactose residues to enter the cell (). HuH-7 cells were used to study AAV5 preferential in vitro transduction by sialic acid residues. HuH-7 cells are human differentiated hepatocytes derived from a cellular carcinoma cell line (Figure 1B).
The CHO Lec-2 cells were inoculated with each capsid at an MOI of 1 × 106 GC/cell using GFP as a transgene and monitored over time to assess the ability of capsids to express a transgene. All capsids showed GFP expression 7 days after inoculation (Figure 1C). To verify the potency of AAV-PhP.B, CHO Lec-2 cells were transduced with each capsid in a 10-fold serial dilution, starting with an MOI of 4 × 106 GC/cell. A dose–response was observed for each capsid, showing the potency of the capsids (Figure 1D). No difference was found in the transduction efficiency of AAV9-PhP.B vs. AA9 (Figure 1D). As expected, the potency of AAV5 and AAV5-PhP.B was lower. Surprisingly, in HuH7 cells, the addition of PhP.B to AAV5 resulted in a significant reduction in transgene activity (Figure 1E).
At a Low Dose, AAV9-PhP.B Can Cross the BBB to Reach the Mouse Brain
AAV5, AAV5-PhP.B, AAV9, and AAV9-PhP.B were evaluated in vivo in C57Bl/6 mice for their capacity to cross the BBB following IV injection and a life period of 6 weeks. Mice were administered a relatively low dose (2.5 × 1011 GC/mouse) of each capsid containing GFP as transgene (Figure 2A). Vector distribution was assessed in the cortex, striatum, and thalamus by qPCR. Only AAV9-PhP.B showed significant transduction to all three investigated brain areas (Figure 2B). However, the numbers of vector copies were very low to generate a positive GFP staining on IHC sections. The addition of the PhP.B peptide to AAV5 did not alter the ability of this capsid to cross the BBB (Figure 2B).
FIGURE 2
AAV5-PhP.B Shows Increased GFP mRNA Expression in Mice Liver
In vitro experiments showed a reduction in transduction and luciferase expression in AAV5-PhP.B-transduced HuH-7 cells compared with AAV5 and no difference between AAV9 and AAV9-PhP.B. We also assessed the transduction of peripheral organs in vivo and liver GFP mRNA expression in mice. A trend is observed in the higher levels of AAV9 and AAV9-PhP.B vector in the spleen. In the kidney, most of the vector is found in animals administered with AAV9-PhP.B. For the liver, there appears to be an equal distribution with the least amount of vector DNA retrieved from mice administered with AAV9-PhP.B-GFP (Figure 3A). GFP mRNA expression was significantly higher in animals administered with AAV5-PhP.B and AAV9 when compared to mice administered with AAV5 or AAV9-PhP.B (Figure 3B).
FIGURE 3
Central Nervous System Transduction of AAV9-PhP.B
Genomic copies of AAV were detected and quantified after IV administration of AAV9-PhP.B. However, no GFP expression was observed in brain sections (data not shown) using the relatively low viral dose. To assess the extent of the AAV9-PhP.B-mediated transduction, GFP-transgene-carrying AAV9-PhP.B was administered at a relatively high dose (4 × 1012 GC/mouse) to demonstrate the presence of transgene protein within the range of detection (Figure 4A). GFP expression was observed throughout the brain from the medulla to the frontal cortex. Positive neurons and astrocytes were identified by shape and location in the medulla (Figure 4B), the locus coeruleus (Figure 4C), the thalamus (Figure 4D), the hippocampus (Figure 4E), the striatum (Figure 4F), and the cortex (Figure 4G). These results highlight the potential of AAV9-PhP.B to express transgene throughout the CNS.
FIGURE 4
Intrastriatal Delivery of AAV5-miRNA Results in High Distribution and Levels of microRNA in Mouse Brain
After establishing that AAV9-PhP.B delivers transgene throughout the mouse brain, we assessed if AAV9-PhP.B could be used for predominantly adult-onset diseases such as HD or Parkinson’s disease. For HD, various huntingtin-gene-expression-lowering strategies are in development (). At the moment, in preclinical studies, IStr administration is the method applied to reach the areas affected in HD. This experiment also aimed to evaluate if AAV9-PhP.B administered by IV could be used as a noninvasive alternative to deliver miRNA in mice.
AAV5 or AAV9-PhP.B containing a miRNA expression cassette (Figure 5A) was produced and administered IStr (1 × 1011 GC/mouse) or IV (4 × 1012 GC/mouse) at an equal concentration (2.7 × 1013 GC/ml), adjusting the volume to the method used (Figure 5B). This is the highest dose that could be produced without the possible formation of aggregates. No significant difference was observed when AAV9-PhP.B was administered IV or IStr. Significantly higher vector genome levels were retrieved from the striatum (Figure 5C) and the cortex (Figure 5D) of mice administered with AAV5-miRNA IStr compared with the other experimental groups. When compared to an IV administration of AAV9-PhP.B, a 22-fold and 15-fold higher vector distribution was achieved in the striatum and cortex, respectively. The levels of miRNA following AAV had a similar pattern as vector DNA found in the striatum (Figure 5E) and the cortex (Figure 5F).
FIGURE 5
Discussion
In this study, AAV9-PhP.B and AAV5-PhP.B were produced in the baculovirus expression system and showed to transduce cells in vitro. Subsequently, these constructs were evaluated in vivo. Although the addition of PhP.B does not enhance BBB crossing of serotype GFP-carrying AAV5, it does increase GFP mRNA expression in the liver. We found that the addition of PhP.B to AAV9 enhances the capability of the vector to cross the BBB, as found in the earlier studies (; ; ), and, when applied at a sufficient dose, GFP expression can be noted throughout the brain from the medulla to the cortex. IStr and IV administration of AAV9-PhP.B mediated similar transduction levels in the cortex and striatum. When we compared IStr administration of AAV5 to IV administration of AAV9, AAV5 IStr was superior in terms of transducing the cortex and striatum.
Overall, we observed lower transduction levels with AAV9 vectors using a similar dose as described in the study first describing PhP.B (). The difference in the quantification method per laboratory could be a possible explanation for observed differences. In addition, for AAV9, varying results are reported between laboratories with regard to the distribution patterns. For example, in one of the first studies, predominant astrocyte transduction () was reported while another laboratory observed the transduction of neurons (). Another observation is more variation in the group of animals administered IStr compared with the IV-injected group. Vector spread after the striatal infusion is not homogenous throughout the tissue since this is performed with concentrated vector directly into tissue resulting in local differences. Therefore, more variation is observed between mice. We suspected that transfer of a homogenous dilution in blood from the endothelium to the striatal area occurs in a more homogenous manner and is, therefore, less sensitive to variation between animals.
The addition of PhP.B to AAV5 resulted in increased transgene mRNA in the liver compared with AAV5. Ly6a is constitutively expressed by liver sinusoidal endothelial cells (LSEC) (). The LSEC form a permeable barrier between the bloodstream and hepatocytes (). In the brain, the interaction between AAV9-PhP.B and Ly6A facilitates the crossing of the BBB. Since we did not note the crossing of the BBB by AAV5-PhP.B, the LSEC may be transduced rather than the hepatocytes underneath.
A recent publication () showed that AAV9 after infection could mediate expression in different cell types in the brain, depending on the promoter used. Moreover, a six alanine insertion after the VP2 start residue results in a shift from oligodendrocyte to neuronal transduction. The addition of PhP.B to AAV could also have an effect on the specific cells transduced within the tissue. Recently, RNAscope in situ hybridization revealed the precise location of the vector DNA and mRNA produced, while identifying specific cells by IHC (). This method could be applied in the future to investigate and differentiate between level of vector entry and transgene expression in a specific cell. In our case, this would be a method to investigate the liver transduction by AAV5-PhP.B. Since this method is beyond the scope of this study, we did not pursue this further.
The question remains why AAV9 is enhanced by PhP.B to cross the BBB, while AAV5 is not. The mechanism by which AAV crosses the BBB has not been fully understood. AAV9 appears to cross the BBB by transcytosis in an in vitro human BBB model by a yet unknown receptor (). The data in mice indicated that AAV9-PhP.B crosses the BBB by transcytosis of brain microvascular endothelial cells (). The results of this study with AAV5-PhP.B indicate that PhP.B alone is not enough for an AAV particle to cross the endothelial barrier. Therefore, it appears PhP.B facilitates the transduction of endothelial cells which in turn enables the enhanced trafficking of AAV9 through the endothelium from apical to basolateral side by another co-receptor. For AAV5-PhP.B endocytosis and trandusction of the endothelium might still occur but the astrocytes and neurons underneath remain untransduced.
The addition of different peptides to the corresponding position I587 in AAV2 enhanced the AAV2 ability to transduce the CNS after IV administration (). Therefore, it is theoretically possible to add a peptide to an AAV serotype other than AAV9 and increase BBB crossing. Each of the serotypes uses a different primary receptor. AAV2 binds to heparin sulfate proteoglycan (HSPG), AAV9 to N-linked galactose receptors, and AAV5 to N-linked sialic acid (). However, both AAV2 and AAV9 use laminin receptor (LamR) as a secondary receptor, while AAV5 also binds the platelet-derived growth factor receptor (PDGF-R) (). The interplay between these various receptors appears to play a role in various transduction patterns.
The AAV9-based IV therapy in combination with a PhP.B designed for primate could be a viable option for diseases with multifocal pathologies where different types of cells in the body are affected, such as lysosomal storage diseases (). In most cases, ideally, therapy should be applied as early as possible before irreversible neurodegeneration occurs (). Due to the more permissiveness of the BBB, newborn babies need a lower dose for disease correction, implying a lower risk of the therapy. In diseases where the whole body is genetically affected, the systemic mechanism of AAV9-primate PhP.B might even be an advantage.
For a clinical application, a primate permissive version of PhP.B should be developed. A putative human equivalent of murine Ly6a, the receptor to which PhP.B binds, is Ly6E. The Ly6E protein is highly expressed in human BBB endothelial cells. Furthermore, a peptide sequence within HIV-GP120 is hypothesized as a potential binding motif functioning as a primate permissive PhP.B (). This peptide could be used to develop a human variant of AAV9-PhP.B to be tested in nonhuman primates or in vitro systems that mimic the human BBB.
Our results further show that the direct administration of AAV5 represents an attractive strategy for diseases where the deeper brain areas have to be targeted. AAV5 has been studied for localized administration to various CNS targets such as intrathalamic pathway () in the deep cerebellar nuclei () and IStr. The IStr administration of AAV5 has been extensively studied in multiple models. Our current transduction results are in line with those of a rodent preclinical HD model in which disease amelioration was achieved (). The IStr administration of AAV5 has also been studied in nonhuman primates () and minipigs (). A similar transduction pattern is observed across all studied species, with high transduction and transgene expression levels in the striatum and cortex. A clinical study using the IStr administration of AAV5 has been initiated in patients with HD (NCT04120493).
We studied the transduction and miRNA expression in the cortex and striatum following AAV delivery. Irrespective of the delivery method, similar transduction and transgene expression levels are observed in the brain with AAV9-PhP.B, showing that for an AAV9 vector with PhP.B or similar enhancement, there would be no added benefit of an IStr over IV delivery. From the standpoint of a clinical program targeting solely the striatum and the connection areas, it is worth investing in IStr delivery with AAV5 rather than further optimizing AAV9 or another capsid to reach the striatum after IV delivery.
Taken together, our results show that for therapies where high levels of transduction are needed, the direct delivery of AAV5 is a viable option. For treatments in which a wide viral spreading throughout the brain and body is desired, a human-targeting variant of AAV9-PhP.B is an attractive candidate.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation upon request.
Ethics statement
The animal study was reviewed and approved by Animal Welfare Body AMC.
Author contributions
KP and BB: conceptualization and initial draft. KP, FP, SP, JL, and BB: investigation. SD, PK, GM, and BB: supervision and editing. All authors contributed to the article and approved the submitted version.
Funding
This study was financially supported by uniQure.
Acknowledgments
We would like to thank S. Baatje, C. Brouwers, L. Paerels, I. Hinojo, and the vector development group for their technical assistance. We would also like to thank E. Broug, R. Martier, and E. Sawyer for critically reviewing this manuscript.
Conflict of interest
KP, FP, SP, SD, JL, PK, and BB were employees of uniQure at the time the data wad generated. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BellC. L.GurdaB. L.VlietK.Agbandje-McKennaM.WilsonJ. M. (2012). Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid.J. Virol.867326–7333. 10.1128/JVI.00448-412
2
BosmaB.du PlessisF.EhlertE.NijmeijerB.de HaanM.PetryH.et al (2018). Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system.Gene Ther.25415–424. 10.1038/s41434-018-0034-37
3
CaronN. S.SouthwellA. L.BrouwersC. C.CengioL. D.XieY.BlackH. F.et al (2019). Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.Nucleic Acids Res.4836–54. 10.1093/nar/gkz976
4
ChenW.HuY.JuD. (2020). Gene therapy for neurodegenerative disorders: advances, insights and prospects.Acta Pharm. Sinica B101347–1359. 10.1016/j.apsb.2020.01.015
5
ChenY. H.ChangM.DavidsonB. L. (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy.Nat. Med.151215–1218. 10.1038/nm.2025
6
DevermanB. E.PravdoP. L.SimpsonB. P.KumarS.ChanK. Y.BanerjeeA.et al (2016). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.Nat. Biotechnol.34204–209. 10.1038/nbt.3440
7
EmborgM. E.HurleyS. A.JoersV.TrompD. P. M.SwansonC. R.Ohshima-HosoyamaS.et al (2014). Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery.Stereotactic Funct. Neurosurg.92182–194. 10.1159/000360584
8
EversM. M.MiniarikovaJ.JuhasS.VallèsA.BohuslavovaB.JuhasovaJ.et al (2018). AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington disease minipig model.Mol. Ther.262163–2177. 10.1016/j.ymthe.2018.06.021
9
FoustK. D.NurreE.MontgomeryC. L.HernandezA.ChanC. M.KasparB. K. (2008). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.Nat. Biotechnol.2759–65. 10.1038/nbt.1515
10
GrayS. J.MatagneV.BachaboinaL.YadavS.OjedaS. R.SamulskiJ. R. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.Mol. Ther.191058–1069. 10.1038/mt.2011.72
11
HordeauxJ.WangQ.KatzN.BuzaE. L.BellP.WilsonJ. M. (2018). The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice.Mol. Therapy26664–668. 10.1016/j.ymthe.2018.01.018
12
HordeauxJ.YuanY.ClarkP. M.WangQ.MartinoA. R.SimsJ. J.et al (2019). The GPI-linked protein LY6A (SCA-1) drives AAV-PHP.B transport across the blood-brain barrier.Mol. Therapy27912–921. 10.1016/j.ymthe.2019.02.013
13
HuangQ.ChanK. Y.TobeyI. G.ChanY. A.PoterbaT.BoutrosC. L.et al (2019). Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids.PLoS One14:e0225206. 10.1371/journal.pone.0225206
14
IlleA. M.KishelE.BodeaR.IlleA.LamontH.Amico-RuvioS. (2020). Protein LY6E as a candidate for mediating transport of adeno-associated virus across the human blood-brain barrier.J. Neurovirol.26769–778. 10.1007/s13365-020-00890-899
15
KeskinS.BrouwersC. C.Sogorb-GonzalezM.MartierR.DeplaJ. A.VallèsA.et al (2019). AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes.Mol. Ther. Methods Clin. Dev.15275–284. 10.1016/j.omtm.2019.09.010
16
KhabouH.DesrosiersM.WincklerC.FouquetS.AureganG.BemelmansA.-P.et al (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8: mechanisms of enhanced transduction by AAV2-7m8.Biotechnol. Bioeng.1132712–2724. 10.1002/bit.26031
17
KotinR. M.SnyderR. O. (2017). Manufacturing clinical grade recombinant adeno-associated virus using invertebrate cell lines.Hum. Gene Therapy28350–360. 10.1089/hum.2017.042
18
LiguoreW. A.DomireJ. S.ButtonD.WangY.DufourB. D.SrinivasanS.et al (2019). AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared to mice.Mol. Ther.272018–2037. 10.1016/j.ymthe.2019.07.017
19
LunaG.PaezJ.CardierJ. E. (2004). Expression of the hematopoietic stem cell antigen Sca-1 (LY-6A/E) in liver sinusoidal endothelial cells: possible function of sca-1 in endothelial cells.Stem Cells Dev.13528–535. 10.1089/scd.2004.13.528
20
MartierR.LiefhebberJ. M.García-OstaA.MiniarikovaJ.Cuadrado-TejedorM.EspelosinM.et al (2019a). Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy.Mol. Therapy - Nucleic Acids1626–37. 10.1016/j.omtn.2019.02.001
21
MartierR.Sogorb-GonzalezM.Stricker-ShaverJ.Hübener-SchmidJ.KeskinS.KlimaJ.et al (2019b). Development of an AAV-Based MicroRNA gene therapy to treat machado-joseph disease.Mol. Ther. Methods Clin. Dev.15343–358. 10.1016/j.omtm.2019.10.008
22
MassaroG.HughesM. P.WhalerS. M.WallomK.-L.PriestmanD. A.PlattF. M.et al (2020). Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes.Hum. Mol. Genet.291933–1949. 10.1093/hmg/ddz317
23
MatsuzakiY.KonnoA.MochizukiR.ShinoharaY.NittaK.OkadaY.et al (2018). Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.Neurosci. Lett.665182–188. 10.1016/j.neulet.2017.11.049
24
MatsuzakiY.TanakaM.HakodaS.MasudaT.MiyataR.KonnoA.et al (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice.Mol. Ther.27700–704. 10.1016/j.ymthe.2019.02.016
25
MendellJ. R.Al-ZaidyS.ShellR.ArnoldD. W.Rodino-KlapacL. R.PriorT. W.et al (2017). Single-Dose Gene-Replacement therapy for spinal muscular atrophy.N. Engl. J. Med.3771713–1722. 10.1056/nejmoa1706198
26
MerkelS. F.AndrewsA. M.LuttonE. M.MuD.HudryE.HymanB. T.et al (2017). Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells.J. Neurochem.140216–230. 10.1111/jnc.13861
27
MijanovićO.BrankovićA.BorovjaginA. V.ButnaruD. V.BezrukovE. A.SukhanovR. B.et al (2020). Battling neurodegenerative diseases with adeno-associated virus-based approaches.Viruses12:460. 10.3390/v12040460
28
MiniarikovaJ.EversM.KonstantinovaP. (2018). Translation of microRNA-based huntingtin lowering therapies from preclinical studies to the clinic.Mol. Ther.26947–962. 10.1016/j.ymthe.2018.02.002
29
MiniarikovaJ.ZimmerV.MartierR.BrouwersC. C.PythoudC.RichetinK.et al (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease.Gene Ther.24630–639. 10.1038/gt.2017.71
30
MorabitoG.GiannelliS. G.OrdazzoG.BidoS.CastoldiV.IndrigoM.et al (2017). AAV-PHP.B-Mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy.Mol. Therapy252727–2742. 10.1016/j.ymthe.2017.08.004
31
PoissonJ.LemoinneS.BoulangerC.DurandF.MoreauR.VallaD.et al (2017). Liver sinusoidal endothelial cells: physiology and role in liver diseases.J. Hepatol.66212–227. 10.1016/j.jhep.2016.07.009
32
PowellS. K.SamulskiR. J.McCownT. J. (2020). AAV capsid-promoter interactions determine CNS cell selective gene expression in vivo.Mol. Ther.281373–1380. 10.1016/j.ymthe.2020.03.007
33
SamaranchL.BlitsB.SebastianS. W.HadaczekP.BringasJ.SudhakarV.et al (2017). MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain.Gene Ther.24253–261. 10.1038/gt.2017.14
34
SpronckE. A.BrouwersC. C.VallèsA.de HaanM.PetryH.van DeventerS. J.et al (2019). AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models.Mol. Ther. - Methods Clin. Dev.13334–343. 10.1016/j.omtm.2019.03.002
35
TardieuM.ZérahM.GougeonM.-L.AusseilJ.de BournonvilleS.HussonB.et al (2017). Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.Lancet Neurol.16712–720. 10.1016/s1474-4422(17)30169-30162
36
UrabeM.DingC.KotinR. M. (2002). Insect cells as a factory to produce adeno-associated virus Type 2 vectors.Hum. Gene Ther.131935–1943. 10.1089/10430340260355347
37
VanceM. A.MitchellA.SamulskiR. J. (2015). Gene Therapy - Principles and Challenges.IntechOpen: Doaa Hashad. 10.5772/61988
38
ZhangH.YangB.MuX.AhmedS.SuQ.HeR.et al (2011). Several rAAV vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system.Mol. Therapy191440–1448. 10.1038/mt.2011.98
39
ZhaoJ.YueY.PatelA.WasalaL.KarpJ. F.ZhangK.et al (2020). High-resolution histological landscape of AAV DNA distribution in cellular compartments and tissues following intramuscular and intravenous injection.Mol. Ther. Methods Clin. Dev.18856–868. 10.1016/j.omtm.2020.08.006
Summary
Keywords
aav, intrastriatal, intravenous, CNS, PhP.B
Citation
Pietersz KL, Plessis FD, Pouw SM, Liefhebber JM, van Deventer SJ, Martens GJM, Konstantinova PS and Blits B (2021) PhP.B Enhanced Adeno-Associated Virus Mediated-Expression Following Systemic Delivery or Direct Brain Administration. Front. Bioeng. Biotechnol. 9:679483. doi: 10.3389/fbioe.2021.679483
Received
11 March 2021
Accepted
24 June 2021
Published
03 August 2021
Volume
9 - 2021
Edited by
Georg A. Feichtinger, Evotec GT, Austria
Reviewed by
Nihay Laham Karam, University of Eastern Finland, Finland; Shen Shen, Biogen Idec (United States), United States
Updates
Copyright
© 2021 Pietersz, Plessis, Pouw, Liefhebber, van Deventer, Martens, Konstantinova and Blits.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bas Blits, b.blits@nin.knaw.nl
†Present address: Bas Blits, Sana-Gen, Amsterdam, Netherlands
This article was submitted to Preclinical Cell and Gene Therapy, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.